N-(1-phenylpropyl)prop-2-enamide | 1242592-13-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1-phenylpropyl)prop-2-enamide
• CAS: 1242592-13-7
• 化学式: C₁₂H₁₅NO
• 分子量: 189.257
• InChiKey: CPAPKLJUFRMRMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-苯丙醇 、 丙烯腈 在 HClO4-functionalized silica-coated magnetic nanoparticles [γ-Fe2O3@SiO2-HClO4] 作用下， 反应 4.0h， 以94%的产率得到N-(1-phenylpropyl)prop-2-enamide
  参考文献：
  名称：

  在令人难以置信的绿色协议下进行Ritter反应：纳米磁性二氧化硅负载的布朗斯台德酸催化剂

  摘要：

  的HClO 4 -官能化二氧化硅涂覆的磁性纳米颗粒[γ-的Fe 2 ö 3 @SiO 2 -HClO 4 ]（2.5摩尔％）已被发现是用于各种醇对应高效转化能生物相容的和可回收的催化剂通过改进的Ritter反应获得酰胺，收率良好。由于可以通过使用外部磁性装置简单地除去这种多相催化剂，然后进行回收，因此，它还可以提高产品纯度，并有望带来经济效益。

  DOI：

  10.1016/j.apcata.2010.06.014

文献信息

• [EN] MALIC ENZYME INHIBITORS<br/>[FR] INHIBITEURS D'ENZYME MALIQUE
  申请人：SUN PHARMA ADVANCED RES CO LTD

  公开号：WO2021074898A1

  公开（公告）日：2021-04-22

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.

  本发明涉及一种新型化合物，可用作苹果酸酶（ME）抑制剂，以及用于制备这些化合物的方法和利用这些化合物治疗由ME介导的疾病，如人类的癌症（例如胰腺导管腺癌（PDAC））。
• Backfilling process
  申请人：ALLIED COLLOIDS LIMITED

  公开号：EP0329409A2

  公开（公告）日：1989-08-23

  A subterranean chamber is backfilled using a slurry of fine particulate material that has been flocculated using a water soluble polymeric flocculant formed from monomeric material that comprises 2-acrylamido methyl propane sulphonate or other sulphonic monomer.

  使用由 2-丙烯酰胺基甲基丙烷磺酸盐或其他磺酸单体组成的单体材料形成的水溶性聚合物絮凝剂絮凝的细颗粒材料泥浆回填地下腔室。
• Malic enzyme inhibitors
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD

  公开号：US11225480B2

  公开（公告）日：2022-01-18

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.

  本发明涉及可用作苹果酸酶（ME）抑制剂的新型化合物、其制备工艺以及这些化合物用于治疗由ME介导的疾病，如人类癌症（如胰腺导管腺癌（PDAC））。这些新型化合物具有符合式 I 的结构 或其药学上可接受的盐、立体异构体或氚代类似物，其中 X、R1、R2 和 Y 如本文所述。
• RESIN FOR NANOIMPRINTING, LAMINATE CONTAINING RESIN FOR NANOIMPRINTING, PRINTED BOARD CONTAINING RESIN FOR NANOIMPRINTING, AND METHOD FOR PRODUCING NANOIMPRINT SUBSTRATE
  申请人：JAPAN SCIENCE AND TECHNOLOGY AGENCY

  公开号：US20150298387A1

  公开（公告）日：2015-10-22

  Provided is a resin for nanoimprinting, which is capable of preventing removal of a transfer-receiving resin from a substrate when a mold is separated during nanoimprinting, and which is also capable of transferring a pattern on a mold to a transfer-receiving resin with high accuracy during thermal nanoimprinting, while improving the throughput. A resin for nanoimprinting, which is represented by formula (1). (In the formula, each of R 1 -R 5 independently represents —H or —OH, and at least one of the R 1 -R 5 moieties represents —OH; R 6 represents a linear, branched or cyclic alkyl group having 1-20 carbon atoms, an aryl group having 6-20 carbon atoms or an aralkyl group having 7-20 carbon atoms; X represents an amide or an ester; Y may be absent, or represents an amide or an ester; P represents an integer of 1-10; and each of m and n represents an integer of 1 or more.)
• MALIC ENZYME INHIBITORS
  申请人：SUN PHARMA ADVANCED RESEARCH COMPANY LTD

  公开号：US20210115038A1

  公开（公告）日：2021-04-22

  The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.